LY3457263

DRUG4 trials

Sponsors

Eli Lilly and Company

Conditions

Diabetes Mellitus, Type 2HealthyObesityOverweightType 2 Diabetes

Phase 1

A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes

CompletedNCT04641312

Eli Lilly and CompanyHealthy, Type 2 Diabetes

Start: 2020-11-25End: 2021-12-21Updated: 2022-01-11

A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

CompletedNCT05377333

Eli Lilly and CompanyDiabetes Mellitus, Type 2

Start: 2022-06-02End: 2023-11-22Updated: 2024-01-11

A Study of LY3457263 in Obese Participants

CompletedNCT05582096

Eli Lilly and CompanyObesity, Overweight

Start: 2022-11-11End: 2023-06-08Updated: 2023-07-18

Phase 2

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

RecruitingNCT06897475

Eli Lilly and CompanyType 2 Diabetes

Start: 2025-03-28End: 2027-06-01Target: 200Updated: 2026-09-14